The contribution of cyclosporine A to the understanding and treatment of autoimmune diseases
- 1 February 1999
- journal article
- review article
- Published by Elsevier BV in Transplantation Proceedings
- Vol. 31 (2), 16S-18S
- https://doi.org/10.1016/s0041-1345(98)02075-2
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Treatment of Recalcitrant Plaque Psoriasis with a Humanized Non-depleting Antibody to CD4Journal of Autoimmunity, 1998
- REGULATION OF TRANSFORMING GROWTH FACTOR-β1 AND ITS RECEPTOR BY CYCLOSPORINE IN HUMAN T LYMPHOCYTESTransplantation, 1995
- Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trialBritish Journal of Dermatology, 1993
- In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A.The Journal of Experimental Medicine, 1993
- Anti-CD4 monoclonal antibody therapy in severe psoriasisJournal of Autoimmunity, 1992
- The risk of neoplasms in patients treated with cyclosporine AJournal of Autoimmunity, 1989
- Effects of cyclosporine in severe systemic lupus erythematosusThe Journal of Pediatrics, 1987
- Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.JCI Insight, 1987
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisNew England Journal of Medicine, 1987
- CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSETThe Lancet, 1986